Antiviral activity of dasatinib and imatinib mesylate. Vero E6 cells were infected with MERS-CoV or SARS-CoV at an MOI of
 0.1 or 1, respectively, and treated for 48 h with eight doses of dasatinib (A) or imatinib mesylate (B). Antiviral activity
 is shown in blue, and cytotoxicity is shown in red. EC50s are indicated. Results are representative of one experiment (means ± SEM; n = 2).

Antiviral activity of dasatinib and imatinib mesylate. Vero E6 cells were infected with MERS-CoV or SARS-CoV at an MOI of 0.1 or 1, respectively, and treated for 48 h with eight doses of dasatinib (A) or imatinib mesylate (B). Antiviral activity is shown in blue, and cytotoxicity is shown in red. EC50s are indicated. Results are representative of one experiment (means ± SEM; n = 2).

Source publication
Article
Full-text available
Outbreaks of emerging infections present the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically clinicians are left with general supportive care and often untested convalescent plasma as available treatment options. Repurposing of approved ph...

Contexts in source publication

Context 1
... drugs. Twenty-seven specific drugs inhibited both MERS-CoV and SARS-CoV infection (Table 2; see also Fig. S1 and S2 in the supplemental material). We present a selection of drugs in Fig. 2, 3, and 4 that are particularly interesting because they have similar structures or similar mechanisms of action or have been tested against other viruses. Data on antiviral activity and cytotox- icity for the remaining compounds that inhibit MERS-CoV and SARS-CoV are provided in the supplemental ...
Context 2
... can lead to chronic myelogenous leukemia. Both imatinib mesylate and dasatinib were developed and approved as inhibitors of this pathway for treating human cancers, including chronic myelogenous leuke- mia (33,34). Both imatinib mesylate and dasatinib inhibit SARS- CoV and MERS-CoV with micromolar EC 50 s (range, 2.1 to 17.6 M) and low toxicity (Fig. 3A and B). SARS-CoV does appear to be more sensitive to both ABL1 inhibitors; for example, the EC 50 of dasatinib against SARS-CoV is 2.1 M, whereas for MERS-CoV the EC 50 is 5.4 M (Fig. 3A). A third ABL1 inhibitor, nilotinib, was also used in this study. Nilotinib is able to inhibit SARS-CoV with a micromolar EC 50 and low toxicity (data not ...
Context 3
... leuke- mia (33,34). Both imatinib mesylate and dasatinib inhibit SARS- CoV and MERS-CoV with micromolar EC 50 s (range, 2.1 to 17.6 M) and low toxicity (Fig. 3A and B). SARS-CoV does appear to be more sensitive to both ABL1 inhibitors; for example, the EC 50 of dasatinib against SARS-CoV is 2.1 M, whereas for MERS-CoV the EC 50 is 5.4 M (Fig. 3A). A third ABL1 inhibitor, nilotinib, was also used in this study. Nilotinib is able to inhibit SARS-CoV with a micromolar EC 50 and low toxicity (data not shown) but does not significantly inhibit MERS-CoV, with the maximum inhibition of MERS-CoV being 39% at the highest dose tested (data not shown). However, the fact that nilotinib is ...

Similar publications

Article
Full-text available
The importation of infectious diseases during a mass gathering may result in outbreaks. Infectious diseases associated with mass gatherings vary depending on the type and location of the mass gathering. The annual Hajj to Makkah in Saudi Arabia is one of the largest annual religious mass gatherings in the world. Preparation for the Hajj encompasses...
Article
Full-text available
Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic...
Article
Full-text available
Middle East Respiratory Syndrome (MERS) is a highly lethal pulmonary infection caused by a previously unidentified coronavirus (CoV), likely transmitted to humans by infected camels. There is no licensed vaccine or antiviral for MERS, therefore new prophylactic and therapeutic strategies to combat human infections are needed. In this study, we desc...

Citations

... Thus, this drug can affect dual targets of spike glycoprotein and main protease of the coronavirus. Nilotinib which is also used for treatment of chronic myelogenous leukemia has shown to inhibit MERS-CoV at 5.5 micromolar and SARS-CoV at 2.1 micromolar concentration [13] . Saquinavir is a drug used in anti-retroviral therapy has been shown to produce anti-viral activity against SARS-CoV2 in a study conducted in Shanghai [14] . ...
Preprint
Identification of potential drug-target interaction for approved drugs serves as the basis of repurposing drugs. Studies have shown polypharmacology as common phenomenon. In-silico approaches help in screening large compound libraries at once which could take years in a laboratory. We screened a library of 1050 FDA-approved drugs against spike glycoprotein of SARS-CoV2 in-silico. Anti-cancer drugs have shown good binding affinity which is much better than hydroxychloroquine and arbidol. We have also introduced a hypothesis named “Bump” hypothesis which and be developed further in field of computational biology.
... Toremifene, the first generation of nonsteroidal SERM, was reported to block various viral infections at low micromolar concentration, including Ebola virus 26,27 , MRES-CoV 28 , SARS-CoV-1 29 , and SARS-CoV-2 30 (Figure 3A). ...
Preprint
There have been more than 850,000 confirmed cases and over 48,000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic, caused by novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), in the United States alone. However, there are currently no proven effective medications against COVID-19. Drug repurposing offers a promising way for the development of prevention and treatment strategies for COVID-19. This study reports an integrative, network-based deep learning methodology to identify repurposable drugs for COVID-19 (termed CoV-KGE). Specifically, we built a comprehensive knowledge graph that includes 15 million edges across 39 types of relationships connecting drugs, diseases, genes, pathways, and expressions, from a large scientific corpus of 24 million PubMed publications. Using Amazon AWS computing resources, we identified 41 repurposable drugs (including indomethacin, toremifene and niclosamide) whose therapeutic association with COVID-19 were validated by transcriptomic and proteomic data in SARS-CoV-2 infected human cells and data from ongoing clinical trials. While this study, by no means recommends specific drugs, it demonstrates a powerful deep learning methodology to prioritize existing drugs for further investigation, which holds the potential of accelerating therapeutic development for COVID-19.
... Finally, several studies have screened hundreds of molecules and tested their activity against MERS-CoV [79][80][81][82][83][84][85] and SARS-CoV-1 [79,80,86]. Old drugs previously used in medical practice have been retested on new emerging viruses [87]. ...
Article
Introduction: Coronavirus has been responsible for several virus outbreaks since 2003, caused by SARS-CoV-1, MERS-CoV, and currently SARS-CoV-2 (COVID-19), the causative agent of coronavirus disease in 2019. COVID-19 has become a global public health emergency because of its high virulence and mortality capacity. This patent review aims to provide an overview of the patents that present possible treatments for SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Areas covered: To treat SARS, MERS and SARS-CoV-2, researchers have filed patents for a number of therapeutic agents. Most of the treatments found were protease inhibitors aimed at proteases such as PLpro, 3CLpro, RNA helicase, and Spike protein, or used monoclonal antibodies and interferons. In addition, the use of Chinese folk medicine and its multitude of medicinal plants with strong antiviral properties was reinforced. Thus, these therapies used in previous epidemics can serve as an aid in the new pandemic by SARS-CoV-2 and be a starting point for new treatments. Expert opinion: The various antiviral alternatives presented in this review offer therapeutic options to fight coronavirus infections. If shown to be effective, these drugs may be extremely important in the current pandemic.
... Despite these translational challenges, current approaches to target host proteins are primarily based on either boosting innate anti-viral immune response, in particular interferon response, or targeting proteins and processes mediating viral infection, such as ACE2 receptors (14), cell surface and endosomal proteases (15), and clathrin mediated endocytosis (16). Moreover, broad availability of high-throughput screening approaches has allowed the purposing and repurposing of drugs based on their effect on virus replication (16)(17)(18)(19), leading to identification of several anti-coronavirus candidates, such as chloroquine, tamoxifen, dasatinib and lopinavir, among others (16,19). Yet, this approach is limited by the idiosyncratic nature of the in vitro models used in antiviral screens and by drug concentrations that may not be achievable in patients (5). ...
Preprint
Full-text available
Most antiviral agents are designed to target virus-specific proteins and mechanisms rather than the host cell proteins that are critically dysregulated following virus-mediated reprogramming of the host cell transcriptional state. To overcome these limitations, we propose that elucidation and pharmacologic targeting of host cell Master Regulator proteins--whose aberrant activities govern the reprogramed state of coronavirus-infected cells--presents unique opportunities to develop novel mechanism-based therapeutic approaches to antiviral therapy, either as monotherapy or as a complement to established treatments. Specifically, we propose that a small module of host cell Master Regulator proteins (ViroCheckpoint) is hijacked by the virus to support its efficient replication and release. Conventional methodologies are not well suited to elucidate these potentially targetable proteins. By using the VIPER network-based algorithm, we successfully interrogated 12h, 24h, and 48h signatures from Calu-3 lung adenocarcinoma cells infected with SARS-CoV, to elucidate the time-dependent reprogramming of host cells and associated Master Regulator proteins. We used the NYS CLIA-certified Darwin OncoTreat algorithm, with an existing database of RNASeq profiles following cell perturbation with 133 FDA-approved and 195 late-stage experimental compounds, to identify drugs capable of virtually abrogating the virus-induced Master Regulator signature. This approach to drug prioritization and repurposing can be trivially extended to other viral pathogens, including SARS-CoV-2, as soon as the relevant infection signature becomes available.
... Existe um potencial para uso dos moduladores seletivos de receptores de estrogênio (SERMS) como drogas anticoronavirus, que podem ter um valor substancial para o tratamento a curto prazo da Covid-19 aguda, principalmente em protocolos de pesquisa. O desafio agora é estabelecer estratégias específicas, limitando o risco de eventos adversos, em uma corrida contra o tempo (Dyall et al., 2014;Dyall et al., 2017). ...
... HCQ is primarily an anti-malarial drug which is also used in autoimmune diseases [11][12][13], sarcoidosis [14], rheumatoid arthritis [15], alopecia areata [16], lupus erythematosus [17], anti-thrombotic [18] and antineoplastic treatment [19]. Moreover, HCQ shows potential antiviral activity and therapeutic use against Ebola [20], Marburg [20], Zika [21], HIV-1 [22], Dengue [23], Chikunguniya [24], Hepatitis C [25], MERS-CoV [26] and SARS-CoV [27] virus treatment. ...
Article
Full-text available
Hydroxychloroquine (HCQ) as a drug grabbed serious attention of whole world in dealing with COVID-19 pandemic. Recently some in-vitro and in-vivo study showing possible inhibition of SARS-CoV-2 by use of HCQ. However at the same time, some case studies showing NO clinical benefit/ poor clinical outcome with substantial detrimental adverse effects by use of HCQ in treatment of coronavirus disease-2019. Thus, the HCQ use (in COVID-19 treatment) is of current international interest, although a consensus has not yet been reached. More evidences are still required to prove efficacy of HCQ against COVID-19. In view of this, the present review highlights the current ongoing research related to use of HCQ in treatment coronavirus disease-2019. The present review will discuss the possible anti-viral mechanism of HCQ, prophylaxis strategy and effect of HCQ against SARS-CoV-2 virus in-vitro study. Further this review also summarizes and debates all available clinical trials/ case studies of HCQ use against COVID-19 (with clinical outcome). Finally possible detrimental adverse effects are also discussed considering the public health and pharmacovigilance concern. Keywords: Potency of hydroxychloroquine; COVID-19; Coronavirus disease-2019; Clinical trials; SARS-CoV-2; Adverse effects of hydroxychloroquine; Pharmacovigilance concern
... Previous studies highlighted that many SARS-CoV M pro inhibitors displayed efficacy against MERS-CoV. 17, 18 The SARS-CoV M pro exists as a homodimer in the crystal structure, 19 and the important residues along with their key roles are listed in Table 1. The key residues that stabilize the dimeric structure of SARS-CoV M pro are shown in Figure 3. ...
Article
A new coronavirus (CoV) caused a pandemic COVID-19, which has become a global health care emergency in the present date. The virus has been termed as SARS-CoV-2 (Severe Acute Respiratory Syndrome-Cororavirus-2) and has a genome similar (~82%) to the SARS-CoV (SARS coronavirus). An attractive therapeutic target for CoVs is the Mpro (main protease) or 3CLpro (3-chymotrypsin-like cysteine protease) as the enzyme plays a key role in the polyprotein processing and is active in a dimeric form. Further, Mpro is highly conserved among various CoVs as the mutation in Mpro is often lethal to the virus. Thus, drugs targeting Mpro enzyme significantly reduce the risk of mutation-mediated drug resistance and display broad-spectrum antiviral activity. The combinatorial design of peptide-based inhibitors targeting the dimerization of SARS-CoV Mpro represent a potential therapeutic strategy. In this regard, we compiled the literature reports highlighting the effect of mutations and N-terminal deletion of residues of SARS-CoV Mpro on its dimerization and thus, catalytic activity. We believe that the present review will stimulate research in this less explored, yet quite significant area. The effect of the COVID-19 epidemic and the possibility of future CoV outbreaks strongly emphasize the urgent need for the design and development of potent antiviral agents against CoV infections.
... It inhibited ZIKV, DENV, HCV, MERS-CoV, SARS-CoV, SARS-CoV-2, RRV, SINV, WNV, YFV, EBOV, LASV, RABV, VSV and HSV-1 viruses (https://doi.org/10.1101/2020.03.25.008482) (Boonyasuppayakorn et al., 2014;Dyall et al., 2014;Hulseberg et al., 2019;Mazzon et al., 2019;Sakurai et al., 2018;Zhou et al., 2017). It could be pursued as a potential anti-SARS-CoV-2 drug candidate. ...
Preprint
Full-text available
As of May 2020, the number of people infected with SARS-CoV-2 continues to skyrocket, with more than 4,3 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. Developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent plasma and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here we developed a neutralization assay using SARS-CoV-2 virus and monkey Vero-E6 cells. We identified most potent sera from recovered patients for treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against SARS-CoV-2 infection in Vero-E6 cells and identified antiviral activity of nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that combinations of virus-directed drug nelfinavir with host-directed drugs, such as salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine exhibit synergistic effect against SARS-CoV-2 in vitro. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.
... µM (ie, ~242-1515 ng/mL), 14 15 similar to the EC50 observed in SARS-CoV-1 and MERS-CoV. 13 Ninety per cent inhibition of SARS-CoV-2 (EC90) with HCQ was achieved at ~5-15 µM (~1679-5038 ng/mL), while clearance required ~20 µM (~6717 ng/mL). 14 15 Importantly, both EC50 and EC90 concentrations may be insufficient to improve clinical outcomes. ...
Article
No abstract available Keywords: epidemiology; hydroxychloroquine; lupus erythematosus, systemic; pharmacokinetics. Conflict of interest statement
... In addition to its antipsychotic activity, a growing body of in vitro studies has demonstrated antiviral properties, for example against influenza (3), hepatitis viruses (4), alphaviruses (5), JC virus (6), Japanese encephalitis virus (7), bronchitis-virus (8), MHV-2 (9), Zika virus (10) or dengue virus (11). CPZ has also been shown to have antiviral activity against coronaviruses in multiple studies (12)(13)(14). It was identified active against both MERS-CoV and SARS-CoV-1 in a screen of 348 FDA-approved drugs, together with three other compounds (chloroquine, loperamide, lopinavir), using different cell lines (12). ...
Preprint
Full-text available
Urgent action is needed to fight the ongoing COVID-19 pandemic by reducing the number of infected people along with the infection contagiousness and severity. Chlorpromazine (CPZ), the prototype of typical antipsychotics from the phenothiazine group, is known to inhibit clathrin-mediated endocytosis and acts as an antiviral, in particular against SARS-CoV-1 and MERS-CoV. In this study, we describe the in vitro testing of CPZ against a SARS-CoV-2 isolate in monkey and human cells. We evidenced an antiviral activity against SARS-CoV-2 with an IC50 of ~10μM. Because of its high biodistribution in lung, saliva and brain, such IC50 measured in vitro may translate to CPZ dosage used in clinical routine. This extrapolation is in line with our observations of a higher prevalence of symptomatic and severe forms of COVID-19 infections among health care professionals compared to patients in psychiatric wards. These preclinical findings support the repurposing of CPZ, a largely used drug with mild side effects, in COVID-19 treatment.